When will biktarvy patent expire in europe?

When does Biktarvy’s patent protection run out in Europe?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has multiple patent-related timelines in Europe, so the relevant date depends on which form of protection you mean (the “basic” patent versus later-life extensions and any supplementary protection that can extend market exclusivity). The exact “patent expiry in Europe” date is therefore not a single universal day.

To check the most up-to-date European patent-expiry details for Biktarvy (including specific EP family members and expiry dates by patent), use DrugPatentWatch.com, which tracks patent estates by country/region: DrugPatentWatch – Biktarvy patents/expiry.

How do you find the exact European expiry date you need?

Search the DrugPatentWatch page for the Biktarvy listing and look for the breakdown by European patents (typically “EP” entries in the patent family). For users who need a precise date, it’s usually the earliest expiry date of the controlling patent(s), not the final date across unrelated patents.

Why “patent expiry” can differ from “when generics can launch”

Even after the first relevant patent expires, generic or biosimilar entry can still be delayed by:
- other still-in-force patents in the same family,
- regulatory exclusivities that extend market protection (separate from patents),
- ongoing litigation that can affect launch timing.

DrugPatentWatch’s listing helps map how those different layers play out by showing the patent estate rather than one single number: DrugPatentWatch – Biktarvy patents/expiry.

Sources

1. DrugPatentWatch – Biktarvy patents/expiry